Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Open access
Florou, Vaia, Rosenberg, Andrew E., Wieder, Eric, Komanduri, Krishna V., Kolonias, Despina, Uduman, Mohamed, Castle, John C., Buell, Jennifer S., Trent, Jonathan C., Wilky, Breelyn A. · 2019 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Angiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative nature, successful management of localized angiosarcoma is often challenging. Systemic chemotherapy is used in the metastatic setting and occasionally in patients with high-risk localized disease in neoadjuvant or adjuvant settings. However, responses tend to be short-lived and most patients succumb to metastatic disease. Novel therapies are needed for patients with angiosarcomas. METHODS: We performed a retrospective analysis of patients with locally advanced or metastatic angiosarcoma, who were treated with checkpoint inhibitors at our institution. We collected their clinical information and outcome measurements. In one patient with achieved complete response, we analyzed circulating and infiltrating T cells within peripheral blood and tumor tissue. RESULTS: We have treated seven angiosarcoma (AS) patients with checkpoint inhibitors either in the context of clinical trials or off label [Pembrolizumab + Axitinib (NCT02636725; n = 1), AGEN1884, a CTLA-4 inhibitor (NCT02694822; n = 2), Pembrolizumab (n = 4)]. Five patients had cutaneous angiosarcoma, one primary breast angiosarcoma and one radiation-associated breast angiosarcoma. At 12 weeks, 5/7 patients (71%) had partial response of their lesions either on imaging and/or clinical exam and two (29%) had progressive disease. 6/7 patients are alive to date and, thus far, 3/7 patients (43%) have progressed (median 3.4 months)- one achieved partial response after pembrolizumab was switched to ongoing Nivolumab/Ipilimumab, one died of progressive disease at 31 weeks (primary breast angiosarcoma) and one was placed on pazopanib. One patient had a complete response (CR) following extended treatment with monotherapy AGEN1884. No patient experienced any ≥ grade 2 toxicities. CONCLUSIONS: This case series underscores the value of targeted immunotherapy in treating angiosarcoma. It also identifies genetic heterogeneity of cutaneous angiosarcomas and discusses specific genetic findings that may explain reported benefits from immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0689-7

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 185

Metadata

Authors
Florou, V., Rosenberg, A. E., Wieder, E., Komanduri, K. V., Kolonias, D., Uduman, M., Castle, J. C., Buell, J. S., Trent, J. C., & Wilky, B. A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-08-08
Volume
7
Issue
1
Pages
213-213
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2967881599
Cited by
185
References
5
FWCI
8.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. https://app.cochat.ai/papers/10.1186/s40425-019-0689-7
The paper
Florou, V., Rosenberg, A. E., Wieder, E., Komanduri, K. V., Kolonias, D., Uduman, M., Castle, J. C., Buell, J. S., Trent, J. C., & Wilky, B. A. (2019). Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0689-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.